AU2019257632A1 - Use of neutrophil elastase inhibitors in liver disease - Google Patents

Use of neutrophil elastase inhibitors in liver disease Download PDF

Info

Publication number
AU2019257632A1
AU2019257632A1 AU2019257632A AU2019257632A AU2019257632A1 AU 2019257632 A1 AU2019257632 A1 AU 2019257632A1 AU 2019257632 A AU2019257632 A AU 2019257632A AU 2019257632 A AU2019257632 A AU 2019257632A AU 2019257632 A1 AU2019257632 A1 AU 2019257632A1
Authority
AU
Australia
Prior art keywords
compound
liver disease
treatment
phenyl
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019257632A
Other languages
English (en)
Inventor
Hoyoung Huh
Brian Roberts
Sanjeev Satyal
Scott Savage
Xueyan Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
pH Pharma Co Ltd
Original Assignee
pH Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by pH Pharma Co Ltd filed Critical pH Pharma Co Ltd
Publication of AU2019257632A1 publication Critical patent/AU2019257632A1/en
Priority to AU2024227697A priority Critical patent/AU2024227697A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2019257632A 2018-04-24 2019-04-22 Use of neutrophil elastase inhibitors in liver disease Abandoned AU2019257632A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024227697A AU2024227697A1 (en) 2018-04-24 2024-10-28 Use of neutrophil elastase inhibitors in liver disease

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862662074P 2018-04-24 2018-04-24
US62/662,074 2018-04-24
PCT/US2019/028551 WO2019209738A1 (en) 2018-04-24 2019-04-22 Use of neutrophil elastase inhibitors in liver disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024227697A Division AU2024227697A1 (en) 2018-04-24 2024-10-28 Use of neutrophil elastase inhibitors in liver disease

Publications (1)

Publication Number Publication Date
AU2019257632A1 true AU2019257632A1 (en) 2020-11-26

Family

ID=68236763

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019257632A Abandoned AU2019257632A1 (en) 2018-04-24 2019-04-22 Use of neutrophil elastase inhibitors in liver disease
AU2024227697A Abandoned AU2024227697A1 (en) 2018-04-24 2024-10-28 Use of neutrophil elastase inhibitors in liver disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024227697A Abandoned AU2024227697A1 (en) 2018-04-24 2024-10-28 Use of neutrophil elastase inhibitors in liver disease

Country Status (11)

Country Link
US (2) US10806735B2 (https=)
EP (1) EP3784657A4 (https=)
JP (1) JP2021522247A (https=)
KR (1) KR20210002573A (https=)
CN (1) CN113614070A (https=)
AU (2) AU2019257632A1 (https=)
CA (1) CA3101274A1 (https=)
IL (1) IL278207A (https=)
SG (1) SG11202010521VA (https=)
TW (1) TW202011965A (https=)
WO (1) WO2019209738A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
AU2020336272A1 (en) 2019-08-23 2022-04-14 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CN114375193B (zh) 2019-09-12 2024-05-14 拓臻制药公司 甲状腺激素受体β激动剂化合物
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
JP2023539639A (ja) 2020-08-25 2023-09-15 イーライ リリー アンド カンパニー Ｓｓａｏ阻害剤の多形
US20220098184A1 (en) * 2020-09-11 2022-03-31 Terms Pharmaceuticals, Inc. Solid dispersion formulations of an fxr agonist
CN114085173B (zh) * 2021-10-18 2024-04-16 嘉兴学院 一种2-硝基-4-甲砜基苯甲醛的制备方法
CN115976192A (zh) * 2022-12-02 2023-04-18 西安华壹健康医学检验实验室有限公司 一种用ne基因表达量检测评估脂肪肝的方法
CN117357508B (zh) * 2023-11-03 2024-05-17 中山大学孙逸仙纪念医院 西维来司他在制备治疗原发性胆汁性胆管炎的药物中的应用
CN119499379B (zh) * 2024-09-23 2025-09-05 广东医科大学 Elane基因作为心力衰竭靶点的制药用途和西维来司他的新用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8288402B2 (en) * 2007-12-20 2012-10-16 Bayer Intellectual Property Gmbh 4-(4-cyano-2-thioaryl)dihydropyrimidinones and their use
US9475779B2 (en) * 2014-07-31 2016-10-25 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
BR112017004708A2 (pt) * 2014-09-12 2017-12-05 Tobira Therapeutics Inc terapia de combinação de cenicriviroc para o tratamento de fibrose
WO2016050835A2 (en) 2014-10-02 2016-04-07 Ruprecht-Karls-Universität Heidelberg Selective inhibitors of neutrophil elastase for treating neuropathic pain and chronic pain states harbouring a neuropathic component
JP2018501276A (ja) * 2015-01-09 2018-01-18 ギリアド アポロ， エルエルシー 非アルコール性脂肪肝疾患の処置のためのａｃｃ阻害剤併用療法
CN110981815A (zh) * 2015-03-18 2020-04-10 Ph制药有限公司 用于生产化合物的方法
US10894054B2 (en) * 2015-04-07 2021-01-19 Intercept Pharmaceuticals, Inc. FXR agonist compositions for combination therapy
WO2017081044A1 (en) 2015-11-13 2017-05-18 Bayer Pharma Aktiengesellschaft 4-(4-cyano-2-thioaryl)dihydropyrimidinones for treating chronic wounds
GB201608453D0 (en) 2016-05-13 2016-06-29 Univ Liverpool Muscle regeneration
EP3518918A4 (en) * 2016-09-28 2020-04-22 Eiger Biopharmaceuticals, Inc. METHOD AND PHARMACEUTICAL COMPOSITIONS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS

Also Published As

Publication number Publication date
JP2021522247A (ja) 2021-08-30
SG11202010521VA (en) 2020-11-27
AU2024227697A1 (en) 2024-11-21
CA3101274A1 (en) 2019-10-31
EP3784657A4 (en) 2022-02-09
CN113614070A (zh) 2021-11-05
EP3784657A1 (en) 2021-03-03
US20190321364A1 (en) 2019-10-24
IL278207A (en) 2020-11-30
US10806735B2 (en) 2020-10-20
KR20210002573A (ko) 2021-01-08
WO2019209738A1 (en) 2019-10-31
US20210069192A1 (en) 2021-03-11
TW202011965A (zh) 2020-04-01

Similar Documents

Publication Publication Date Title
US10806735B2 (en) Use of neutrophil elastase inhibitors in liver disease
JP2017512757A (ja) 経口投与するためのペントサンポリ硫酸塩の組成物および使用の方法
US20090191265A1 (en) Capsule Formulation of Pirfenidone and Pharmaceutically Acceptable Excipients
SK2612002A3 (en) Pharmaceutical formulation containing benzamide derivative with improved solubility and oral absorptivity
US20080300253A1 (en) Treatment of inflammatory disorders with praziquantel
KR20090075792A (ko) 아미딘 관능기를 가진 활성 물질의, 약제에서의 생체이용성의 증대
KR100701539B1 (ko) 멜라가트란의 신규 용도
US6281222B1 (en) Compositions and method for treatment of acetaminophen intoxication
CN116459260A (zh) 一种特异性靶向nlrp3炎症小体抑制剂的用途
US20070197602A1 (en) Combined pharmaceutical composition
EP4208160A1 (en) Ionic liquid formulations for treating diabetes
JPH06329538A (ja) 皮膚疾患処置用薬剤
KR20210079275A (ko) 고콜레스테롤 관련 병으로 치료 받고 있는 환자에서의 당뇨병의 위험 감소 방법
US20220296597A1 (en) Use of a neutrophil elastase inhibitor in lung disease
JPH11246408A (ja) 肝障害治療剤
CN101180053A (zh) 铁在发病机制中发挥作用的肝病的治疗
JPWO2000003734A1 (ja) アレルギー疾患治療剤
JPH09194360A (ja) 肝線維化防止剤
JPWO2000003703A1 (ja) 新規なアレルギー疾患治療剤

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted